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Ipilimumab (IPI) blocks CTLA-4 immune checkpoint resulting in T  cell activation and 
enhanced antitumor immunity. IPI improves overall survival (OS) in 22% of patients with 
metastatic melanoma (MM). We investigated the association of CTLA-4 single nucleo-
tide variants (SNVs) with best overall response (BOR) to IPI and OS in a cohort of 173 
MM patients. Patients were genotyped for six CTLA-4 SNVs (−1661A>G, −1577G>A, 
−658C>T, −319C>T, +49A>G, and CT60G>A). We assessed the association between 
SNVs and BOR through multinomial logistic regression (MLR) and the prognostic effect 
of SNVs on OS through Kaplan–Meier method. Both −1577G>A and CT60G>A SNVs 
were found significantly associated with BOR. In particular, the proportion of responders 
was higher in G/G genotype while that of stable patients was higher in A/A genotype. 
Abbreviations: BOR, best overall response; CTLA-4, cytotoxic T lymphocyte antigen-4; EAP, expanded access program; IMI, 
Italian Melanoma Intergroup; IPI, ipilimumab; MLR, multinomial logistic regression; MM, metastatic melanoma; OS, overall 
survival; PSQ, pyrosequencing; SNVs, single nucleotide variants.
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inTrODUcTiOn
Ipilimumab (IPI) is a human monoclonal antibody targeting the 
immune-checkpoint molecule CTLA-4 (cytotoxic T lymphocyte 
antigen-4), which is expressed on activated effector T cells (Teff 
cells) and regulatory T cells (Tregs). CTLA-4 negatively regulates 
Teff cell activation through inhibition of cell proliferation, IL2 
production, and cell-cycle progression (1, 2) upon binding to B7 
ligands (CD80/CD86) expressed by the antigen-presenting cells. 
IPI inhibits the CTLA-4/B7 interaction, thus promoting costimu-
lation and proliferation of Teff cells as well as their infiltration into 
the tumor (3, 4).
Ipilimumab was approved for the treatment of metastatic 
melanoma (MM) following the demonstration of a statistically 
significant improvement in overall survival (OS) in two rand-
omized phase III trials in pre-treated (5) and treatment-naïve 
(6) MM patients. IPI may achieve clinical benefit in terms of 
long-lasting disease control and long-term survival in ≈20% of 
patients (5, 7).
The increasing number of treatment options available (includ-
ing targeted therapies and other immune-checkpoint inhibitors) 
and the evidence that IPI may achieve a relevant clinical benefit 
(i.e., durable response to treatment and long-term survival) in a 
small subset of patients highlight the need to investigate predic-
tive biomarkers that identify this subset of patients.
In this context, several potential biomarkers have been pro-
posed including serum lactate dehydrogenase (LDH) (8), periph-
eral blood lymphocyte count (8), neutrophil-to-lymphocyte ratio 
(9), intratumoral immune cell infiltration (10), mutational load 
(11), and other parameters underlying cancer-immune cell inter-
actions (12). However, despite some correlations with response to 
IPI, these predictive biomarkers have not yet proved sufficiently 
robust to be used clinically (13).
Single-nucleotide variants (SNVs) of CTLA-4 gene may repre-
sent novel predictive biomarkers in IPI-treated MM patients for 
their influence on the host immune response through alteration 
of CTLA-4 expression levels and function in T  cells, as shown 
primarily in autoimmune diseases (14).
In particular, they can affect the transcriptional efficiency of 
CTLA-4 gene (14–16), CTLA-4 processing and intracellular/
surface transport (17), the interaction between CTLA-4 and 
CD80 ligand (18), and the levels of CTLA-4 soluble isoform (14). 
Thus, it is reasonable that CTLA-4 gene variants may have a role 
also in the response to a CTLA-4-based immunotherapy.
Indeed, CTLA-4 SNVs have shown some implications both in 
clinical response (19) and OS (20) in MM patients treated with 
anti-CTLA-4 therapy. In a previous pilot study, we were able to 
identify two out of six specific CTLA-4 SNVs (namely −1577G>A 
and CT60G>A) as having a potential role in OS and response to 
IPI (20). This preliminary study, conducted on a limited cohort 
of patients, was mainly a hypothesis generating investigation that 
was further assessed in the present multicentre study. We here 
report on the genotype distribution of six functionally relevant 
CTLA-4 variants (SNVs −1661A>G, −1577G>A, −658C>T, 
−319C>T, +49A>G, CT60G>A) in a cohort of 173 MM patients 
treated with IPI and on their association with response to IPI 
treatment and OS.
MaTerials anD MeThODs
Patient Features, iPi Treatment, and 
response evaluation
The present multicenter retrospective study included 173 
patients, aged ≥16, presenting stage IV melanoma with 0–2 
Eastern Cooperative Oncology Group performance status, who 
failed to respond or were intolerant to at least one prior systemic 
treatment and no other therapeutic option.
Among them, 122 were enrolled between July 2010 and January 
2012 within an expanded access program [EAP; Ref. (21)] aimed 
at the compassionate use of IPI. Additional 51 patients were 
enrolled between February 2012 and November 2013 after IPI 
use in Italy had been approved by the AIFA (Agenzia Italiana 
del Farmaco, Rome, Italy). Twelve Italian centers, members of 
the Italian Melanoma Intergroup (IMI) network, participated in 
patient recruitment. The observation period ended by June 30th, 
2015.
Enrolled patients were treated intravenously with IPI 
(3 mg/kg) every 3 weeks (induction dose) for a maximum of four 
doses. Patients treated within the EAP were eligible to receive 
The frequency of patients experiencing progression was similar in all genotypes. MLR 
evidenced a strong downward trend in the probability of responsiveness/progression, 
in comparison to disease stability, as a function of the allele A “dose” (0, 1, or 2) in 
both SNVs with reductions of about 70% (G/A vs G/G) and about 95% (A/A vs G/G). 
Moreover, −1577G/G and CT60G/G genotypes were associated with long-term OS, the 
surviving patients being at 3 years 29.8 and 30.8%, respectively, as compared to 12.9 
and 14.4% of surviving patients carrying −1577G/A and CT60G/A, respectively. MM 
patients carrying −1577G/G or CT60G/G genotypes may benefit from IPI treatment in 
terms of BOR and long-term OS. These CTLA-4 SNVs may serve as potential biomark-
ers predictive of favorable outcome in this subset of patients.
Keywords: cTla-4 variants, melanoma, ipilimumab, best overall response, overall survival, predictive/prognostic 
factor
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re-treatment with IPI 3  mg/kg every 3  weeks for four doses if 
they progressed after achieving disease control during induction 
therapy.
Clinical response was assessed as the best overall response 
(BOR) and classified by the oncologist according to immune-
related response criteria (22) as immune-related complete 
response (irCR) or partial response (irPR) observed at any time 
during the study. The first scheduled tumor assessment was at 
week 12 following IPI initiation. Immune-related stable disease 
(irSD) was defined as failure to meet criteria for irCR or irPR, 
together with absence of progressive disease (irPD).
One hundred unrelated healthy Italian subjects (Transfusion 
Service, IRCCS AOU San Martino-IST, Genova, Italy), matched 
for patient gender and age at the time of first IPI treatment, were 
analyzed as controls, upon written informed consent.
cTla-4 genotyping
Genomic DNA was extracted from whole peripheral blood sam-
ples as already described (23).
Genotyping of CTLA-4 SNVs −1661A>G (rs4553808), 
−1577G>A (rs11571316), −658C>T (rs11571317) in the 
5′UTR and in the promoter region, and CT60G>A (rs3087243), 
present in the 3′UTR of the gene, was performed by previously 
described multiple pyrosequencing (PSQ) methods (23). Briefly, 
the EpMotion5070 liquid handling station (Eppendorf, Milan, 
Italy) was utilized to assemble the PSQ-PCR reactions in a final 
volume of 50  µl containing 200  μmol/LdNTPs, 1× GeneAmp 
buffer (1.5 mM MgCl2), 1.25 U of Immolase Hot Start polymerase 
(Bioline, Milan, Italy), and 0.3 µM of the PCR primer pairs specific 
for every SNV. The sequencing reactions were performed with the 
Pyro Gold reagent kit PSQ 96MA according to the manufacturer 
using a PSQ96MA instrument (Qiagen, Milan, Italy). The SNV 
genotyping was carried out analyzing multiple (for −1661 and 
−658 SNVs) and single PSQ reactions (for −1577 and CT60 
SNVs). The sequencing analysis was conducted with the PSQ™ 
96MA (version 2.02) software.
Genotyping of −319C>T (rs5742909, in the promoter) and 
+49A>G (rs231775, in the exon 1) SNVs was performed by previ-
ously described Tetra-primer Amplification Refractory Mutation 
System PCR [T-ARMS-PCR; Ref. (24)] and part of the results 
were validated with the PSQ assay as previously described (25).
statistical analysis
Comparison of SNV genotype and allele frequencies between 
patients and healthy subjects was performed using the Pearson’s 
χ2 test or the Fisher’s exact test, as appropriate.
Deviation from the Hardy–Weinberg Equilibrium (HWE) was 
analyzed with the Pearson’s χ2 test by using the de Finetti program 
(http://ihg.gsf.de/cgi-bin/hw/hwa1.pl). A P-value <0.05 indicates 
a lack of HWE.
Patients and disease characteristics were explored using 
descriptive statistics and expressed as relative frequencies 
(percentages) for discrete variables and medians for continuous 
variables.
The primary endpoint was the relationship between each 
SNV and BOR. In this context, a multinomial logistic regres-
sion (MLR) was applied to the three-level clinical response 
(BOR: irPR +  irCR, irSD, and irPD) in order to estimate the 
predictive role of SNVs while controlling for some important 
characteristics (age, gender, visceral metastases, LDH levels, and 
number of pre-IPI therapies) (26). MLR can be considered as an 
extension of the more widely used logistic regression modeling 
for dichotomous outcome (i.e., responders vs non-responders) 
in that it allows to perform simultaneously two binary com-
parisons: irPR +  irCR vs irSD and irPD vs irSD. Within each 
binary comparison, odds ratio (OR) point estimate, with 95% 
confidence interval (95% CI), was computed and considered as 
a relative index of association between SNVs and the clinical 
outcome.
The secondary endpoint was OS as estimated from the date of 
first IPI cycle to the date of last contact or death from any cause. 
OS was analyzed using the Kaplan–Meier method and differences 
between groups were assessed by the log-rank test.
All statistical analyses were carried out using the SPSS package 
(version 20.0 for Windows). Statistical significance was accepted 
for any two-sided P-value < 0.05.
resUlTs
Patient Features, Disease characteristics, 
and Treatment regimes
Overall, the present study included 173 MM patients enrolled 
from July 2010 to November 2013. The observation period ended 
by June 30th, 2015. The primary melanoma subtype, based on 
tumor location, was cutaneous (n = 130, 75.1%), mucosal (n = 17, 
9.8%), or ocular (n = 14, 8.1%) with a distribution in line with 
that reported in the EAP study (21). For the remaining 12 (6.9%) 
patients, the primary tumor site was unknown.
Main patient and disease characteristics are summarized in 
Table 1 together with treatment regimens. By the time of the 
first IPI cycle, 35 (20.2%) patients had brain metastases, 68 
(39.3%) had liver metastases, and 13 (7.5%) had both. Other 
81 (46.8%) patients had metastases at sites different from brain 
and/or liver. For two (1.2%) patients, the site of metastases was 
unknown. Overall, more than one-third of all patients (n = 60, 
34.7%) presented diffused disease with metastases at three or 
more sites.
One hundred and thirty (75.1%) patients received the sched-
uled four doses of IPI; the remaining 43 (24.9%) patients received 
three or less doses.
Most patients (n =  114, 65.9%) received 1 line of systemic 
therapy prior to treatment with IPI, while 45 (26.0%) and 14 
(8.1%) received 2 or ≥3 lines, respectively. Chemotherapy was 
the most frequent regimen used (n = 144, 83.2%) followed by 
immunotherapy (n = 34, 19.7%) and targeted therapy (n = 23, 
13.3%). Among the patients receiving immunotherapy, 22 
received interferon alone and 12 received chemotherapy 
associated with interferon and/or interleukin-2. IPI was never 
administered.
Following IPI therapy, 69 (39.9%) patients among those 
who experienced disease progression received further systemic 
treatment, including chemotherapy, BRAF/MEK inhibitors, anti-
PD-1, or IPI re-treatment.
TaBle 1 | Patient (n = 173) features, disease characteristics, and 
treatment regimens.
characteristic n (%)
Age, years, at first IPI cycle (median, range) 58.9 (26.6–88.2)
Gender
Male 96 (55.5)
Female 77 (44.5)
Primary melanoma subtype
Cutaneous 130 (75.1)
Mucosal 17 (9.8)
Ocular 14 (8.1)
Missing 12 (6.9)
ECOG performance status
0 113 (65.3)
1 51 (29.5)
2 9 (5.2)
Serum LDH
Normal level 65 (37.6)
≥Upper limit of normal 92 (53.2)
Missing 16 (9.2)
Number of metastasis sites at first IPI cycle
1 60 (34.7)
2 51 (29.5)
≥3 60 (34.7)
Missing 2 (1.2)
Brain metastases
Present 35 (20.2)
Absent 136 (78.6)
Missing 2 (1.2)
Liver metastases
Present 68 (39.3)
Absent 103 (59.5)
Missing 2 (1.1)
Other metastases
Present 81 (46.8)
Absent 90 (52.0)
Missing 2 (1.2)
Number of IPI cycles administered
4 130 (75.1)
3 8 (4.6)
2 16 (9.2)
1 19 (11.0)
Number of lines of therapies prior to IPI
1 114 (65.9)
2 45 (26.0)
≥3 14 (8.1)
Chemotherapya prior to IPI
Yes 144 (83.2)
No 29 (16.8)
Immunotherapyb prior to IPI
Yes 34 (19.7)
No 139 (80.3)
Targeted therapyc prior to IPI
Yes 23 (13.3)
No 150 (86.7)
Therapy post-IPId
Yes 69 (39.9)
No 102 (59.0)
Missing 2 (1.1)
IPI, ipilimumab; ECOG, Eastern Cooperative Oncology Group; LDH, lactate 
dehydrogenase.
aIncluding mainly dacarbazine, temozolomide, and fotemustine.
bIncluding mainly interferon alpha and interleukin-2.
cBRAF/MEK inhibitors including vemurafenib, pimasertib, and dabrafenib.
dIncluding IPI, chemotherapy, BRAF/MEK inhibitors, and anti PD-1.
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genotyping and Frequencies of cTla-4 
Variants in MM Patients and control 
subjects
Six CTLA-4 SNVs, −1661A>G, −1577G>A, −658C>T, 
−319C>T, +49A>G, and CT60G>A, were analyzed in 173 MM 
patients and 100 healthy control subjects adequately matched for 
gender and age.
Genotype and allele frequencies are reported in Table 2. As 
shown, no deviation from the HWE was observed for any SNV 
and similar frequencies of genotypes and alleles were found in 
both patient and control groups for all the six CTLA-4 SNVs 
analyzed.
association of cTla-4 Variant genotype 
with response to iPi
Of the 173 patients, 36 (20.8%) showed irPR or irCR, 16 (9.2%) 
showed irSD, and 121 (69.9%) showed irPD (Table 3).
For both −1577G>A and CT60G>A SNVs, patients showed 
a similar frequency of irPD, regardless the genotypes, whereas 
G/G carriers presented a higher rate of irPR + irCR (28.6% for 
−1577G>A and 30.9% for CT60G>A) as opposite to the A/A car-
riers who presented a higher rate of irSD (25.0% for −1577G>A 
and 21.4% for CT60G>A). The G/A carriers presented an inter-
mediate frequency of both irPR +  irCR (19.3% for −1577G>A 
and 20.2% for CT60G>A) and irSD (6.8% for −1577G>A and 
6.7% for CT60G>A) (Table 3, left side).
Multinomial logistic regression analysis confirmed the 
results obtained in descriptive analysis. Considering OR as the 
relative probability of responsiveness/progression vs stability, 
we found a generalized reduction in the proportion of responder 
and progressive patients as the “dose” of allele A increases in 
both SNVs. In particular, using G/G as a reference category, 
G/A showed a probability of irPr + irCR which was on average 
70% lower than the reference (−1577G>A: OR =  0.24, 95% 
CI = 0.02–2.33; CT60G>A: OR = 0.28, 95% CI = 0.03–2.61), 
while A/A experienced a reduction of about 95% (−1577G>A: 
OR  =  0.04, 95% CI  =  0.01–0.44; CT60G>A: OR  =  0.007, 
95% CI = 0.01–0.061). Using the same modeling constraints, 
namely G/A and A/A vs G/G, a very similar tendency in allele A 
“dose” was also observed for irPD vs irSD comparison (Table 3, 
right side).
association of cTla-4 Variant genotype 
with Os
Median follow-up was 8.1  months (range 0.9–58  months). 
Overall, 142 (82.1%) deaths were observed. Among the 31 surviv-
ing patients, 28 (90.3%) had completed the scheduled four cycles 
of IPI.
Correlation of CTLA-4 variants with OS indicated that two of 
the six SNVs, namely −1577G>A and CT60G>A, had a notice-
able effect on long-term OS. During the first 15 months from the 
start of IPI treatment, the mortality rate was similar regardless 
the genotype carried (Figure 1A for −1577G>A and Figure 1B 
for CT60G>A). Thereafter, not only the survival curves started to 
stabilize up to more than 4 years but also to separate. Although 
median OS was similar among all genotypes, a better survival was 
TaBle 3 | association of cTla-4 −1577g>a and cT60g>a snV genotypes with best overall response to ipilimumab in metastatic melanoma patients 
estimated through a multinomial logistic regression modeling.
cTla-4 snV genotype Total irPr + ircr irsD irPD irPr + ircr vs irsD irPD vs irsD
N (%) N (%) N (%) Or 95% ci P-value Or 95% ci P-value
−1577G>A G/G 49 14 (28.6) 1 (2.0) 34 (69.4) 1.00 (Ref.) <0.010 1.00 (Ref.) <0.010
G/A 88 17 (19.3) 6 (6.8) 65 (73.9) 0.24 0.02–2.33 0.26 0.03–2.59
A/A 36 5 (13.9) 9 (25.0) 22 (61.1) 0.04 0.01–0.44 0.05 0.01–0.49
CT60G>A G/G 42 13 (30.9) 1 (2.4) 28 (66.7) 1.00 (Ref.) <0.010 1.00 (Ref.) 0.010
G/A 89 18 (20.2) 6 (6.7) 65 (73.1) 0.28 0.03–2.61 0.31 0.03–2.94
A/A 42 5 (11.9) 9 (21.4) 28 (66.7) 0.07 0.01–0.61 0.10 0.01–0.90
Total per SNV 173 36 (20.8) 16 (9.3) 121 (69.9) – – – – – –
SNV, single nucleotide variant; irPR, immune-related partial response; irCR, immune-related complete response; irSD, immune-related stable disease; irPD: immune-related 
progressive disease; OR, odds ratio adjusted for age, gender, visceral metastases, lactate dehydrogenase levels, and number of pre-IPI therapies; 95% CI, 95% confidence interval 
for OR; P-value, likelihood-based χ2 test for heterogeneity; Ref., reference category.
TaBle 2 | Frequencies of six cTla-4 gene variants in 173 metastatic melanoma patients and in healthy control subjects.
n (%) n (frequency)
genotypes Melanoma patients (n = 173) controls (n = 100) P¶ alleles Melanoma patients (2n = 346) controls (2n = 200) P*
−1661a>g −1661a>g
A/A 102 (59.0) 58 (58.0) 0.868 A 266 (0.77) 154 (0.77) 1.000
A/G 62 (35.8) 38 (38.0) G 80 (0.23) 46 (0.23)
G/G 9 (5.2) 4 (4.0)
HWE P = 0.915 P = 0.466
−1577g>a −1577g>a
G/G 49 (28.3) 26 (26.0) 0.807 G 186 (0.54) 102 (0.51) 0.535
G/A 88 (50.9) 50 (50.0) A 160 (0.46) 98 (0.49)
A/A 36 (20.8) 24 (24.0)
HWE P = 0.761 P = 0.997
−658c>T −658c>T
C/C 139 (80.3) 76 (76.0) 0.669 C 310 (0.89) 175 (0.87) 0.482
C/T 32 (18.5) 23 (23.0) T 36 (0.11) 25 (0.13)
T/T 2 (1.2) 1 (1.0)
HWE P = 0.917 P = 0.607
−319c>T −319c>T
C/C 139 (80.3) 81 (81.0) 0.517 C 311 (0.90) 179 (0.89) 0.884
C/T 33 (19.1) 17 (17.0) T 35 (0.10) 21 (0.11)
T/T 1 (0.6) 2 (2.0)
HWE P = 0.519 P = 0.339
+49a>g +49a>g
A/A 96 (55.5) 55 (55.0) 0.780 A 255 (0.74) 149 (0.75) 0.919
A/G 63 (36.4) 39 (39.0) G 91 (0.26) 51 (0.25)
G/G 14 (8.1) 6 (6.0)
HWE P = 0.425 P = 0.791
cT60g>a cT60g>a
G/G 42 (24.3) 24 (24.0) 0.877 G 173 (0.50) 97 (0.48) 0.790
G/A 89 (51.4) 49 (49.0) A 173 (0.50) 103 (0.52)
A/A 42 (24.3) 27 (27.0)
HWE P = 0.748 P = 0.848
Genotyping of −1661A>G, −1577A>G, −658C>T, and CT60G>A was performed by the pyrosequencing (PSQ) method and genotyping of −319C>T and +49A>G was performed 
by T-ARMS PCR and confirmed by PSQ as described in the Section “Materials and Methods”. Comparison of CTLA-4 genotypic and allelic frequencies between melanoma patients 
and control subjects was estimated using the Pearson’s χ2 test (¶P-value) and the Fisher’s test (*P-value), respectively. Statistical significance: P < 0.05. HWE, Hardy–Weinberg 
equilibrium tested by χ2 test (P < 0.05 indicates a lack of HWE).
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always observed in patients carrying the G/G genotype: regarding 
the −1577G>A SNV carriers, their survival rate was remarkably 
higher as compared to the G/A carriers, being 29.8 vs 12.9%, at 
3 years and 26.9 vs 11.1%, at 4 years (Table 4, log rank p = 0.172, 
not shown). The G/G carriers showed a higher survival rate 
also with respect to the A/A carriers (29.8 vs 19.4%, at 3 years). 
Similarly, a higher percentage of survivors at 3 years was observed 
in the CT60G/G carriers as compared to the CT60G/A carriers, 
being 30.8 vs 14.4% at 3 years (Table 4, log rank p = 0.154, not 
shown). Such difference was maintained at 4 years (27.4 vs 12.6%). 
The CT60A/A carriers showed a survival rate comparable to that 
of the CT60G/A carriers at any time point.
FigUre 1 | Kaplan–Meier curves for overall survival according to the 
homozygous g/g or a/a and the heterozygous g/a genotypes of (a) 
−1577g>a and (B) cT60g>a cTla-4 single nucleotide variants.
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Patients who had received immunotherapy before IPI showed 
a better survival, although not statistically significant, as com-
pared to patients who did not receive any prior immunotherapy 
(median OS 10.2 vs 7.3 months). Moreover, the survival pattern 
according to CTLA-4 genotypes was confirmed also in this 
subgroup of patients since patients with the G/G genotype had 
a more favorable survival compared to patients with the G/A 
genotype for both −1577G>A and CT60G>A SNVs.
DiscUssiOn
The present study assessed the potential role of defined CTLA-4 
gene variants in predicting clinical outcome in patients with 
advanced melanoma treated with IPI. The rationale for this study 
was based on the assumption that, since CTLA-4 represents a 
key negative regulator of T cell activation, genetic variants which 
alter its expression and/or function could affect the interaction of 
CTLA-4 with IPI and thus its therapeutic efficacy in MM patients. 
Indeed, we previously provided some evidences of a possible 
effect of the −1577G>A and CT60G>A SNVs in favoring OS and 
response to CTLA-4 blockade therapies (20).
In the present study, we further confirmed that the CTLA-4 
−1577G>A and CT60G>A SNVs are significantly associated 
with BOR to IPI treatment.
Multinomial logistic regression analysis of BOR was per-
formed using the following covariates: age and gender, as generic 
factors commonly used in statistical analyses; presence of visceral 
metastases as main prognostic factor reflecting the overall clinical 
status of the patient; LDH levels as well established prognostic fac-
tor of survival in melanoma patients; number of therapies given 
before IPI as factor mostly indicative of the clinical history of the 
patient. This analysis pointed out a strong decreasing tendency 
in the relative frequency of responder/progressive patients in 
comparison to stable patients as a function of the allele A “dose” 
(0, 1, and 2) in both SNVs. On average, statistically significant 
reductions of about 70% (G/A vs G/G) and about 95% (A/A vs 
G/G) were found. In other words, harboring the allele A seems to 
induce an effect of disease stability.
The homozygous −1577G/G and/or CT60G/G genotypes also 
appear to favor a long-term survival: patients with these geno-
types had more than a twofold higher survival rate at 3 and 4 years 
compared to patients with the heterozygous G/A genotype.
By contrast, the other −1661A>G, −658C>T, −319C>T, and 
+49A>G SNVs did not present any relevant role in our analysis.
The precise mechanism by which the G/G genotypes are asso-
ciated with a favorable BOR and OS in IPI-treated MM patients 
remains to be determined as no functional data in melanoma 
patients are available in literature. However, a biological role 
for the G/G genotype of both −1577 and CT60 SNVs has been 
reported in healthy individuals being found associated with a 
significant decrease of CTLA-4 mRNA levels and, consequently, 
with a reduced CTLA-4 expression at the surface of peripheral 
blood mononuclear cells (27). Thus, it would be reasonable to 
hypothesize that a lower CTLA-4 expression level would result in 
a lower baseline downregulation of Teff cells and reduced interac-
tion with B7 ligands potentially facilitating the blocking capability 
of IPI. Moreover, the G/G genotype of CT60 SNV might have a 
prognostic value by reducing the frequency of Treg cells (28) as 
well as the levels of soluble CTLA-4 isoform (14).
By contrast, the A/A genotype might correlate with higher 
CTLA-4 expression not only on Teff and Treg cells but also on 
tumor cells (29) thus facilitating tumor cellular lysis through 
an IPI-dependent cell-mediated cytotoxicity by Fcγ receptor 
expressing immune cells, such as monocytes for Treg cells (30) 
or NK and Tγδ cells for tumor cells (29). A higher cytotoxicity 
of Treg or tumor cells might balance the higher downregulation 
of Teff cells harboring the A/A genotype suggesting a possible 
explanation for the higher proportion of MM patients with irSD 
among the A/A carriers.
In view of the increasing number of effective drugs available for 
the treatment of MM, upfront identification of patients who are 
TaBle 4 | Median overall survival (Os) and survival rates for metastatic melanoma patients treated with ipilimumab at defined time intervals.
genotypes Os (months) 1 year 2 years 3 years 4 years
Median 95% confidence interval (95% ci) % 95% ci % 95% ci % 95% ci % 95% ci
−1577g>a
G/G (n = 49) 7.3 1.5–13.2 42.9 29.0–56.8 32.1 19.0–45.2 29.8 16.9–42.7 26.9 13.9–39.8
G/A (n = 88) 7.3 5.2–9.5 37.5 29.4–45.6 20.5 13.8–27.2 12.9 7.1–18.7 11.1 5.5–16.7
A/A (n = 36) 8.3 6.1–11.0 38.9 23.0–54.8 25.0 10.9–39.1 19.4 6.5–32.3 19.4 6.5–32.3
cT60g>a
G/G (n = 42) 7.3 0.9–13.7 45.2 30.1–60.3 33.3 19.0–47.6 30.8 16.7–44.9 27.4 13.5–41.3
G/A (n = 89) 7.2 5.3–9.1 38.2 30.0–46.3 22.0 15.1–28.9 14.4 8.3–20.5 12.6 6.7–18.5
A/A (n = 42) 8.3 6.4–10.3 35.7 21.2–50.2 21.4 9.1–33.7 16.7 5.3–28.1 16.7 5.3–28.1
Median OS and survival rates as estimated from Kaplan–Meier analysis.
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more likely to fail or to benefit from treatment is a major unmet 
need. Regarding IPI, only a small subset of patients experience 
a clinical response to treatment and IPI itself is not devoid of 
adverse events. This is particularly relevant in the adjuvant set-
ting: IPI 10 mg/kg was recently approved by the FDA as adjuvant 
treatment for patients with resected stage III melanoma; however, 
despite a 25% decrease in the risk of relapse compared with pla-
cebo in a phase III trial, more than half of the patients treated with 
IPI experienced a grade 3–4 adverse event and five (1%) patients 
randomized in the IPI arm died because of drug-related adverse 
events (31).
Besides IPI, other biological treatments are now available for 
MM patients. Anti-PD-1 agents have been recently approved by 
the FDA and patients with tumors harboring the BRAF mutation 
may be treated with BRAF and MEK inhibitors. Both anti-PD-1 
drugs and BRAF and MEK inhibitors have been shown to achieve 
better response rates and higher median OS than IPI in clinical 
trials (32–34). Nevertheless, IPI may still have a role as (i) a sub-
sequent therapy in metastatic patients after progressive disease 
with anti-PD-1 and, if BRAF-mutant, BRAF/MEK inhibitors; (ii) 
an adjuvant therapy for high-risk stage III melanoma; and (iii) a 
combination therapy with anti-PD-1 drugs.
In conclusion, our results indicate that the −1577G>A and 
CT60G>A CTLA-4 variants may have some predictive and/or 
prognostic role of IPI efficacy in MM patients. However, this 
concept needs to be validated in further randomized studies 
comparing patients with similar clinicopathological characteris-
tics treated or not with IPI. In this regard, it is noteworthy that 
some CTLA-4 SNVs, including CT60G>A, did not show any 
significant effect in melanoma patients treated with adjuvant 
interferon alpha therapy (25), thus supporting the hypothesis 
of some involvement of determined SNVs in CTLA-4-based 
immunotherapy.
Functional studies are also required to define the mechanisms 
of action of CTLA-4 gene variants on both Teff cells and tumor 
cells in IPI-treated melanoma patients.
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